Sangamo enters into asset sale agreements with Lilly and Astellas

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

STEADFAST: A First-in-Human Study Assessing HLA-A*02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation

Download PDF